Transcript Programma Polo Carmignani ok copia

Endorsed by
DECEMBER 3, 2016 FIRENZE
preliminary program
CONFERENCE REGISTRATION
IPAD 4
Registration fee for non members: € 375,00 + VAT 22%
Registration fee for Accademia Limpe, Sin and EAN members: special rate at € 187,50 + VAT 22%
Registration fee includes: conference kit, admission to all the scientific sessions, lunch and coffee breaks. It is possible to register
online on the Official Site: http://www.ipadcongress.com
CONFERENCE VENUE
HOTEL LONDRA
Via J. Da Diacceto 18
50123 Firenze
www.concertohotels.com
OFFICIAL LANGUAGE
English is the official language of the Conference. No simultaneous translation will be provided.
CONTINUING MEDICAL EDUCATIONS ( CME )
Italian participants will receive Italian CME credits (ECM)
Organizing Secretariat
First Class S.r.l. Meetings and Conferences - Viale Italia, 173 - 57127 Livorno - Via G. Carducci 11, 20123 Milano - Italy
Ph: +39 0586 84 98 11 - Email: [email protected]
Supported by unrestricted educational grants by
TH
WEBSITE http://www.ipadcongress.com
4 INTERNATIONAL CONFERENCE ON
NEW THERAPIES FOR PARKINSON AND
ALZHEIMER DISEASES
SCIENTIFIC BOARD AND FACULTY
CONFERENCE ORGANIZERS
08:45
Ubaldo Bonuccelli - Pisa
Filippo Baldacci - Pisa
Saturday December 3
Sandro Sorbi - Florence
Opening: S. Sorbi, U. Bonuccelli
09:00 - 11:00
Paolo Barone - Salerno
Vincenzo Bonifati - Roma
Carlo Caltagirone - Roma
Roberto Ceravolo - Pisa
Monica Di Luca - Milano
Joaquim J. Ferreira - Lisbon
Laura Fratiglioni - Stockholm
Jean-Charles Lambert - Lille
Wassilios Meissner - Bordeaux
Massimo Musicco - Roma
Benedetta Nacmias - Firenze
The 4th International Conference on New Therapies for Parkinson and
Dementias –IPAD4 will take place in Florence on December 3, 2016.
The conference will bring together experts of neurodegenerative
diseases coming from the academic world, hospital centres and
pharmaceutical industry. The meeting will focus on the new possibilities of preclinical and early diagnosis, and on the more innovative
pharmacological and non-pharmacological therapies.
The results of clinical trials will be evaluated and discussed, as well as
ongoing studies and the expected outcomes, drugs' pipeline, nonpharmacological therapies, perspectives on biomarkers and on future
diagnostic-therapeutic scenario and unmet needs of patients with
parkinsonian syndromes and dementias.
Alessandro Padovani - Brescia
Leandro Provinciali - Ancona
Alberto Pupi - Firenze
Elio Scarpini - Milano
Philip Scheltens - Amsterdam
Eduardo Tolosa - Barcellona
Vissia Viglietta - Boston
Cohort studies: the risk of Parkinson and Dementia - L. Fratiglioni
New frontiers in genetic studies and biomarkers
AD - J. C. Lambert
PD - V. Bonifati
AD/PD - F. Baldacci
Coffee break
11:30 - 13:00
Lunch
14:30 - 16:30
New Therapeutic horizons 1
Chairmen: U. Bonuccelli - B. Nacmias
I-MAO B inhibitors in PD - P. Barone
COMT inhibitors in PD - J. Ferreira
Neurotransmitter drugs in Dementia - M. Di Luca
Amyloid antibodies in AD-focus on aducanumab - V. Viglietta
LOCAL ORGANIZING COMMITTEE
Filippo Baldacci - Pisa
Laura Bracco - Firenze
Daniela Frosini - Pisa
Filippo Giorgi - Pisa
Benedetta Nacmias - Firenze
Alberto Pupi - Firenze
Gloria Tognoni - Pisa
Early diagnosis and Imaging Biomarkers
Chairmen: M. Musicco - A.Padovani
Prodromal AD - S. Sorbi
Prodromal PD - E. Tolosa
AD Imaging - A.Pupi / PD Imaging - R. Ceravolo
Sandro Sorbi - Ubaldo Bonuccelli
Congress Presidents
Werner Poewe - Innsbruck
Epidemiology ,Genetics and Biomarkers: What's new
Chairmen: C. Caltagirone - L. Provinciali
Coffee break
17:00 - 18:30
New Therapeutic horizons 2
Chairmen: S. Sorbi - P. Barone
Antiamyloid and antiTAU drugs in AD - E. Scarpini
Antisynuclein drugs in PD - W. Meissner/W. Poewe
Nutraceutics and dementia - P. Scheltens